Helsinn announces its support for the International Fellowship Program (IFP), a joint project founded by the Society for Translational Oncology (STO) and Chinese Society of Clinical Oncology (CSCO)
Lugano, Switzerland, October 10, 2017 - Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announces its support for the International Fellowship Program (IFP), which is a joint project founded by the US-based professional association Society for Translational Oncology (STO) and Chinese Society of Clinical Oncology (CSCO).
The mission of the program is to address the needs of young Chinese oncologists, the next generation of experts, and aims to enhance the clinical skills, as well as expertise in the design and conduction of clinical trials in oncology during this promising and rapidly evolving era of precision medicines and immuno-oncology. The IFP program is sponsored by Helsinn , OrigiMed and Sanofi .
The winners this year, announced at the recent 20th annual meeting of the STO-CSCO Joint Symposium, were Dr. WEI Jia from Drum Tower Hospital Affiliated to Medical School of Nanjing University, and Dr. YANG Sheng from Cancer Hospital of Chinese Academy of Medical Sciences (CAMS). They will visit the United States for three months and participate in a series of curriculum as well as communication focused on clinical trials, translational medicine and novel drug development led by Harvard Medical School and Alliance for Clinical Trials in Oncology . They will also have the opportunity to visit the US Food and Drug Administration (FDA) to learn and discuss topics of common academic interests.
Hans Schmid, Chairman of the Board of Directors, Helsinn Pharmaceuticals (Beijing) Co. Ltd., added :
"I am delighted to announce today Helsinn's support for the International Fellowship Program, which helps develop young oncologists. I would like to congratulate this year's winners and participants as these young Chinese oncologists are the next generation clinical investigators with outstanding ability and the potential to be the future leaders. They share our values and our commitment to improving the lives of patients living with cancer."
About the Helsinn Group
Helsinn is a privately owned pharmaceutical group with an extensive portfolio of marketed cancer care products and a robust drug development pipeline. Since 1976, Helsinn has been improving the everyday lives of patients, guided by core family values of respect, integrity and quality. The Group works across pharmaceuticals, biotechnology, medical devices and nutritional supplements and has expertise in research, development, manufacture and the commercialization of therapeutic and supportive care products for cancer, pain and inflammation and gastroenterology. In 2016, Helsinn created the Helsinn Investment Fund to support early-stage investment opportunities in areas of unmet patient need. The company is headquartered in Lugano, Switzerland, with operating subsidiaries in Switzerland, Ireland, and the U.S., as well as a product presence in approximately 190 countries globally.
About Society for Translation Oncology (STO)
STO is a non-profit, professional association committed to speeding the discovery and translation of important new treatments in the field of cancer medicine to the practice of global oncology by bringing knowledge and strategies for critical new developments in cancer treatment to the community oncologist, bridging the "translational gap" between discovery and delivery of care to the patient, and providing educational activities to improve physician competencies for screening, prevention, diagnosis, treatment, and supportive care of cancer patients.
About Chinese Society of Clinical Oncology (CSCO)
The Chinese Society of Clinical Oncology (CSCO) is a public academic and professional organization comprised of clinical oncology professionals, relevant entities, and public institutions.
CSCO is committed to developing continuing medical and clinical oncology education, enhancing multi-disciplinary collaboration, encouraging multi-center research, promoting the standardization of tumor diagnosis and treatment, and furthering the development of clinical oncology as a benefit all patients.
For more information:
Helsinn Group Media Contact
Paola Bonvicini
Group Head of Communication
Lugano, Switzerland
Tel: +41 (0) 91 985 21 21
- Please visit www.helsinn.com
- We are on Twitter. Follow us @HelsinnGroup
